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Abstract:
Introduction. Clinical guidelines indicate that haematocrit should be 
monitored during testosterone replacement therapy (TTh) with action 
taken if a level of 0.54 is exceeded. 
Aim. To consider the extent of changes in haematocrit and putative 
effects on viscosity, blood flow and mortality following TTh. 
Methods. We focused on literature describing benefits and possible 
pitfalls of TTh including increased haematocrit. We used data from the 
BLAST RCT to determine change in haematocrit after 30 weeks of TTh 
and describe a clinical case showing the need for monitoring. We 
consider the validity of the current haematocrit cut-off value at which 
TTh may be modified. Ways in which haematocrit alters blood flow in the 
micro- and macro-vasculature are also considered. 
Main Outcome Measures. (1) change in haematocrit, (2) corresponding 
actions taken in clinical practice and (3) possible blood flow changes 
following change in haematocrit. 
Results.  Analysis of data from the BLAST RCT showed a significant 
increase in mean haematocrit of 0.01, the increase greater in men with 
lower baseline values. While, none of 61 men given TTh breached the 
suggested cut-off of 0.54 after 30 weeks, a clinical case demonstrates 
the need to monitor haematocrit. An association between haematocrit 
and morbidity and mortality appears likely but not proven and, may be 
evident only in patient subgroups. The consequences of an increased 
haematocrit may be mediated by alterations in blood viscosity, oxygen 
delivery and flow. Their relative impact may vary in different vascular 
beds.     
Conclusions. TTh can effect an increased haematocrit via poorly 
understood mechanisms and may have harmful effects on blood flow 
that differ in patient subgroups. At present, there appears no scientific 
basis for using an haematocrit of 0.54 to modify TTh; other values may 
be more appropriate in particular patient groups. 
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Abstract.
Introduction. Clinical guidelines indicate that haematocrit should be monitored 
during testosterone replacement therapy (TTh) with action taken if a level of 0.54 is 
exceeded.
Aim. To consider the extent of changes in haematocrit and putative effects on 
viscosity, blood flow and mortality following TTh. 
Methods. We focused on literature describing benefits and possible pitfalls of TTh 
including increased haematocrit. We used data from the BLAST RCT to determine 
change in haematocrit after 30 weeks of TTh and describe a clinical case showing 
the need for monitoring. We consider the validity of the current haematocrit cut-off 
value at which TTh may be modified. Ways in which haematocrit alters blood flow in 
the micro- and macro-vasculature are also considered.
Main Outcome Measures. (1) change in haematocrit, (2) corresponding actions 
taken in clinical practice and (3) possible blood flow changes following change in 
haematocrit. 
Results.  Analysis of data from the BLAST RCT showed a significant increase in 
mean haematocrit of 0.01, the increase greater in men with lower baseline values. 
While, none of 61 men given TTh breached the suggested cut-off of 0.54 after 30 
weeks, a clinical case demonstrates the need to monitor haematocrit. An association 
between haematocrit and morbidity and mortality appears likely but not proven and , 
may be evident only in patient subgroups. The consequences of an increased 
haematocrit may be mediated by alterations in blood viscosity, oxygen delivery and 
flow. Their relative impact may vary in different vascular beds.    
Conclusions. TTh can effect an increased haematocrit via poorly understood 
mechanisms and may have harmful effects on blood flow that differ in patient 
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subgroups. At present, there appears no scientific basis for using a haematocrit of 
0.54 to modify TTh; other values may be more appropriate in particular patient 
groups. 
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Introduction
Use of testosterone therapy (TTh) is increasing rapidly worldwide. For example, in 
the United States the cost of TTh in 2013 was $2.4 billion with an expected increase 
to $3.8 billion in 2018 (https://www.statista.com/statistics/320301/predicted-annual-
testosterone-drug-revenues-in-the-us/ - accessed on 01/11/2018). Though the 
benefits of TTh in terms of reduced risk of cardiovascular disease (CVD) and 
mortality are reported in an increasing number of studies, some reports present a 
contrary view. This review is in two sections; the first considers the merits of TTh in 
men with low serum testosterone and associations between increased haematocrit, 
a well recognised adverse effect of the therapy, and morbidity / mortality. The 
second part considers the association between haematocrit and blood flow and 
discusses putative mechanisms whereby TTh may lead to development of 
pathology. Our approach has been to review the literature and present unpublished 
data from our BLAST randomised controlled trial that describes the relationship 
between TTh, increased haematocrit, morbidity and mortality. The importance of 
monitoring haematocrit is emphasised in a case report showing TTh leading to a 
markedly increased haematocrit requiring phlebotomy and replacement of injectable 
TTh with a gel formulation.  We also speculate on the effect that increased numbers 
of red cells could have on blood flow characteristics in different vascular beds. The 
review is based on publications from basic science, longitudinal and randomised 
controlled trials and reviews known to us or selected from Pubmed (US National 
Library of Medicine). 
Testosterone Deficiency. 
Testosterone deficiency (TD), characterised by low testosterone levels and related 
symptoms, occurs in 6–12% of men [1,2]. TD is associated with decreased bone 
Page 4 of 37
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mineral density, lean mass, muscle strength, cognitive function, sexual function and 
increased fat mass [1,2,3]. The phenotype is categorised as primary TD, secondary 
TD (pituitary/hypothalamic disease) or adult onset TD. Adult onset TD describes in 
men older than 50 years (following exclusion of hypothalamic-pituitary-testicular axis 
pathology), a combination of low serum testosterone levels and accompanying 
symptoms The condition is associated with obesity, type 2 diabetes (T2DM) and the 
metabolic syndrome (MetS) [3,4]. Prevalence of adult onset TD in men with T2DM is 
about 40% [5,6]. Indeed, low testosterone levels are associated with the number and 
severity of components classifying the metabolic syndrome (increased waist 
circumference / body mass index, glycaemia, triglycerides, blood pressure and 
decreased high density lipoprotein cholesterol) and , may also predict the onset of 
diabetes in younger men [7].
Importantly, adult onset TD is associated with increased morbidity and mortality [4]. 
For example, the European Male Ageing study, (2599 men, (7% withT2DM, aged 40-
79 years, about 4 years follow-up) showed the combination of TD symptoms and 
total testosterone <8nmol/l (230.5ng/dl) was significantly associated with increased 
total and CVD mortality [7]. Importantly, there is also accumulating evidence from 
longitudinal observational studies that TTh can lead to improved sexual health and 
reduced all-cause mortality [4]. Shores et al studied the impact of TTh on mortality in 
1031 males (aged over 40 years, total testosterone≤ 8.7 nmol/l (250.7ng/dl), mean 
follow-up about 4 years),  mortality in 398 men on TTh was 10.3%), compared with 
untreated controls (20.7%) [9]. Survival analysis showed significantly reduced 
mortality in men with T2DM but not in their non-diabetic counterparts. This finding 
was confirmed by 2 longitudinal studies of men with T2DM. Muraleedaran et al 
studied over 6 years, the effects of low testosterone (the cohort stratified by total 
Page 5 of 37
Sexual Medicine Reviews
Sexual Medicine Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
testosterone of 10.4 nmol/l (299.7ng/dl)) and TTh on mortality in 581 men with T2DM 
[10]. Mortality was higher in 238 men with low testosterone (HR: 2.02, 95% CI: 1.2 - 
3.4) compared to those with values above 10.4 nmol/l (299.7ng/dl) after adjustment 
for confounders. In the low testosterone group, the 174 men not on TTh were at 
significantly higher risk of mortality (HR: 2.3, 95% CI: 1.3 - 3.9) than the 64 men 
receiving TTh. A longitudinal study in 857 men with T2DM by our group showed 
similar results [11]. We stratified the cohort using a total testosterone cut-off of 12.0 
nmol/l (345.8ng/dl) and free testosterone of 0.25 nmol/l (7.2ng/dl); over a mean 3.8 
years, mortality was reduced in men on TTh with greatest benefit in older men 
[11,12]. Survival analysis (adjusted for age, phosphodiesterase 5-inhibitor and statin 
treatment) showed that compared with men with low testosterone (either low total or 
calculated free testosterone) not on TTh, mortality was lower in men with normal 
testosterone (HR: 0.62, CI: 0.41 - 0.94) and men with low testosterone on TTh (HR: 
0.38, CI: 0.16 - 0.90). This benefit was independent of changes in conventional 
cardiovascular/metabolic risk factors (weight, body mass index, dyslipidaemia, 
glycaemic control, blood pressure) [13]. Further, Snyder et al. in the Testosterone 
trial, showed significant benefits in sexual function, mood, depression, quality of life, 
physical performance, vitality, anaemia and bone mineral density in the overall 
group, although this benefit was not evident in the individual studies [14]. The BLAST 
randomised controlled study suggested improvements in erectile dysfunction 
following TTh, especially in men with total testosterone levels < 8nmol/l; the change 
reaching statistical significance only after 6 months of therapy [15, 16] with 
improvement continuing even after 4 years [17].
The above data provides the basis for the British Society for Sexual Medicine [4] and 
International Society for Sexual Medicine guidelines 
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(https://professionals.issm.info/wp-content/uploads/sites/2/2018/05/ISSM-Quick-
Reference-Guide-on-TD.pdf - accessed on 02/01/2019) that include the following 
management recommendations; 
 Total testosterone <8nmol/l (230.5ng/dl) or free testosterone <0.180nmol/l 
(5.2ng/dl): usually requires TTh.
 Total testosterone >12nmol/l (345.8ng/dl) or free testosterone >0.225nmol/l 
(6.5ng/dl) : does not require TTh.
 Total testosterone 8-12nmol/l (230.5-345.8ng/dl) may require a trial of TTh for 
a minimum of 6 months depending on symptoms.
Possible cardiovascular adverse effects associated with TTh. 
Concern continues to exist (https://www.fda.gov/Drugs/DrugSafety/ucm436259.htm - 
accessed on 02/01/2019) 
(http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Test
osterone_31/Recommendation_provided_by_Pharmacovigilance_Risk_Assessment
_Committee/WC500175213.pdf - accessed on 02/01/2019 ) regarding the 
cardiovascular safety of TTh in the treatment of adult onset TD. Thus, while most 
studies demonstrate either benefit or no increase in cardiovascular events, a few 
widely cited studies have reported increased CVD in patients on TTh [18,19]. Vigen 
et al used a composite of all-cause mortality, myocardial infarction and stroke rates 
as outcome in patients with low testosterone levels who had undergone coronary 
angiography and subsequently received TTh [20]. Though the event rate was 10.1% 
in testosterone treated and 21.2% in untreated patients, after adjustment for over 50 
variables (baseline testosterone and erectile dysfunction, both associated with all-
cause mortality were not included), TTh appeared associated with increased events 
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(25.7% in treated, 19.9% in untreated groups) during 3 years follow-up. Finkle et al 
examined 55,593 insurance claims and compared the incidence rate of myocardial 
infarction in the 12 months prior and 3 months after the initial prescription of TTh and 
reported an increased rate of non-fatal myocardial infarctions especially in men aged 
65 years or older [21]. In younger men, the risk was confined to those with pre-
existing heart disease. Importantly the control group was comprised of men 
commenced on phosphodiesterase 5-inhibitors which have been demonstrated to 
lower cardiovascular and all-cause mortality [11,12,22,23]. Further, there were 
design flaws including lack of data on testosterone levels, the reporting of only non-
fatal events and a retrospective review of the previous 12 months only after the 
decision on TTh was made. Three months follow up may be insufficient to detect 
benefit from TTh and the authors conceded that increased events could be related to 
TD rather than TTh. Basaria et al published the ‘Testosterone in Older men with 
Mobility Limitations (TOM) Trial’ of 209 older men (mean age: 74 years) with limited 
mobility randomised to either testosterone or placebo gel [24]. Though the primary 
outcome (change in maximal voluntary muscle strength during leg press exercise) 
was met, the trial was discontinued as 23 men given TTh and 5 men given placebo 
appeared to develop cardiovascular related adverse events. However, in addition to 
the limitations imposed by a relative small cohort there was no cardiovascular 
assessment at baseline and events were based on self reporting and included a 
wide range of symptoms including peripheral oedema and syncope. Though these 
studies have flaws and the mechanism for the putative adverse effect of TTh is 
unidentified, they do indicate a need to better assess potential problems in using TTh 
especially in patient subgroups.
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We recently speculated on the effects that patient heterogeneity could have on 
treatment benefits [25]. For example, a small patient subgroup may be at an 
increased risk that cannot be detected in large trials with wide inclusion criteria. 
Accordingly, clinical outcomes associated with TTh need to be identified using 
randomised controlled trials and observational longitudinal studies that evaluate 
benefits and adverse effects in the total cohort and subgroups. 
Increased haematocrit following TTh 
In this context, the effects of TTh on haematocrit and potentially clinical outcome are 
important. Thus, an increase in haematocrit is the commonest adverse effect linked 
with TTh [26, 27,28] with values >0.54 used to alter dose or discontinue treatment 
[4]. 
The need for regular monitoring of haematocrit is exemplified in a case report. 
Patient MM, a male aged 53 years was referred to the metabolic clinic at University 
Hospitals Birmingham NHS Foundation Trust in 2007 with severe fatigue, erectile 
dysfunction and the MetS. He was diagnosed with T2DM in 2012 with a total 
testosterone of 3.6 nmol/l (103.7ng/dl), LH: 0.6IU/l, FSH: 3.6IU/l) and similar values 
on repeat testing (fasting sample at 9 AM). Other biochemical investigations 
including a GnRH dynamic function test were unremarkable. A diagnosis of adult 
onset TD was made and he was commenced on testosterone gel (2%) with 4 
applications/day (each application 10mg testosterone) with haematocrit levels < 0.54 
(0.499 – 0.536) until November 2016 (total testosterone: 6.9nmol/l (198.8ng/dl), 
calculated free testosterone: 0.14nmol/l (4.0ng/dl)). When the testosterone gel was 
increased to 5 daily applications in view of persisting symptoms, the haematocrit 
increased to 0.565 (total testosterone: 12.0nmol/l (345.8ng/dl), calculated free 
testosterone: 0.24nmol/l (6.9ng/dl)). TTh was reduced to 4 applications daily and in 
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view of increasing fatigue levels the patient was referred to the Urology clinic in 
January 2017 and testosterone undecanoate injections were commenced in March 
2017. Energy levels improved with this therapy and in June 2017 total testosterone 
was 13.3nmol/l (383.3ng/dl), calculated free testosterone was 0.25nmol/l (7.2ng/dl) 
and haematocrit was 0.536. The haematocrit had significantly increased at review in 
December 2017; thus, six weeks after testosterone undecanoate administration, total 
testosterone: 28.8nmol/l (830.0ng/dl), calculated free testosterone 0.70nmol/l 
(20.2ng/dl) and haematocrit 0.638. The testosterone undecanoate was immediately 
discontinued and the patient commenced on aspirin. A check after 3 weeks showed 
the haematocrit was 0.648, serum total testosterone was 26.8nmol/l (772.3ng/dl) and 
calculated free testosterone was 0.65nmol/l (18.7ng/dl). The patient underwent 
immediate venesection and the haematocrit gradually reduced; January 2018: 0.557, 
February 2018: 0.544, April 2018: 0.537, July 2018: 0.530. In August 2018 the 
haematocrit was 0.499 with total testosterone of 3.7nmol/l (106.6ng/dl) and 
calculated free testosterone of 0.08nmol/l (2.3ng/dl). The patient was suffering 
severe fatigue and erectile dysfunction and wished to restart testosterone gel. At the 
last follow-up in August 2018 (on 4 gel applications) the haematocrit was 0.507, total 
testosterone 15.4nmol/l (443.8ng/dl) and calculated free testosterone 0.41nmol/l 
(11.8ng/dl) with some clinical improvement.
The patient’s written consent allowing us to describe this case was obtained and filed 
in his hospital notes. It emphasises the need for monitoring and appropriate action 
where needed. As recommended by guidelines, we used a haematocrit of 0.54 as 
threshold for reducing or stopping TTh [4]. This level appears based on the 
haematocrit reference range and not on evidence. Clearly, given data linking 
elevated haematocrit levels with increased morbidity/mortality, an evidence-based 
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threshold value that can be used in clinical practice is needed. A further issue in 
using TTh may be the testosterone preparation and its mode of delivery [28]. A 
recent comprehensive review suggested short-acting, injectable testosterone is 
associated with greater risk of elevated haematocrit compared with other 
preparations [28]. This raises the possibility that the rate of change in serum 
testosterone concentration may be mechanistically important; short-acting injectable 
testosterone could lead to steeper rises and falls in hormone levels that in turn has 
effects on erthrocytosis. However, as demonstrated by the above case, monitoring of 
haematocrit is needed with all testosterone preparations including long-acting 
injectable TTh.  
Change in haematocrit after 30 weeks TTh in the BLAST study 
The BLAST randomised controlled trial (European Union Clinical Trials Register: 
EudraCT 2008-000931-16) comprised a 30 week randomised double-blind placebo-
controlled multicentre study carried out during September 2008 - June 2012 to 
assess the impact of TTh using testosterone undecanoate, a long-acting injectable 
preparation in 199 men with T2DM (primary outcome: change in glycaemic control) 
[29]. Baseline and final visit haematocrit data were available in 134 (placebo: 73 
men, TTh: 61 men) of the 189 men completing the study (placebo: 103 men, TTh: 86 
men). No significant change in haematocrit was observed in the placebo group 
(baseline: 0.432, final visit: 0.435, p (paired t-test) = 0.22). The haematocrit 
increased significantly in the TTh group (baseline: 0.444, final visit: 0.454, p (paired 
t-test) = 0.01) but did not breach the 0.54 threshold in any patient during 30 weeks of 
treatment. 
Haematocrit at baseline was only associated with diastolic blood pressure (linear 
regression, coefficient (c): 0.11, 95% CI: 0.06 - 0.17, p < 0.001). When adjusted for 
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baseline age, total testosterone and other classifying characteristics of the MetS 
(body mass index, triglycerides, HDL-cholesterol, HBA1c, systolic blood pressure), 
this association remained significant (multiple regression, c: 0.07, 95% CI: 0.006 - 
0.14, p = 0.03). Only baseline haematocrit (not age, total / free testosterone level or 
metabolic parameters) was associated with the 0.010 increase in haematocrit in men 
on TTh (c: - 0.35, 95% CI: - 0.56 - - 0.14, p = 0.001). The finding that the coefficient 
had a negative value indicates reassuringly, that lower not higher baseline 
haematocrit levels were associated with the largest increases. No such association 
was observed in the placebo group (c: -0.11, 95% CI: -0.29 – 0.07, p=0.22). Figure 1 
illustrates the change in haematocrit following 30 weeks of treatment with placebo or 
TTh. The negative coefficient observed between baseline and change in haematocrit 
in the BLAST patients differs from data reported by Ip et al who showed higher 
trough testosterone levels predicted an increased haematocrit > 0.50 [30].
The mechanism for increased haematocrit following TTh is unclear. Coviello et al 
demonstrated a linear dose-dependent increase in haemoglobin and haematocrit 
levels following TTh, this observed in both 60 men aged 60 – 75 years and 61 men 
aged 19 – 35 years. However, the increase was more evident in the older men [31]. 
Interestingly, we observed greater reductions in mortality following TTh in older men 
[11,12]. No increase in erythropoietin or the marker of bone marrow erythropoetic 
activity, soluble transferrin receptor, was noted. They speculated androgens may 
have a direct stimulatory effect on the bone marrow and perhaps promote 
differentiation of erythroid colony forming units into erythropoietin sensitive cells. In 
contrast Bachman et al found that an increase in haemoglobin and haematocrit was 
associated with elevated erythropoietin levels 1-3 months following TTh, but the 
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levels returned to normal after 6 months [32]. Despite increased haemoglobin and 
haematocrit, erythropoietin levels were not suppressed.
Elevated haematocrit and increased morbidity / mortality
We now consider longitudinal observational studies that evaluate the association 
between haematocrit and CVD. While no consensus has been reached, there are 
hints of a non-linear relationship. In a meta-analysis of 16 population-based 
prospective studies comprising 8020 individuals (mean haematocrit = 0.440), 
Danesh et al showed the top tertile of haematocrit (haematocrit >0.463) was 
associated with increased coronary heart disease (risk ratio: 1.16, 95% CI: 1.05–
1.29) compared to the bottom tertile (haematocrit < 0.417) [33]. Addition of another 3 
trials comprising individuals with established cardiovascular disease strengthened 
the above association between the 2 extreme tertiles (risk ratio: 1.81, 95% CI: 1.19 – 
2.76). However, the authors urged caution as adjustment for other coronary heart 
disease risk factors which were associated with haematocrit levels, varied between 
the trials. 
These findings were not confirmed by the European Prospective Investigation into 
Cancer and Nutrition - Netherlands (EPIC-NL) study (derived from the MORGEN-
EPIC and Prospect-EPIC studies) comprising 16,187 individuals without CVD at 
baseline [34]. No association was found between the haematocrit tertiles (cut-off 
values 0.45 and 0.47) and 10 year risk of CVD, strokes and coronary heart disease. 
The Scottish Heart Health Extended Cohort Study estimated the predictive value of 
plasma viscosity, haematocrit and whole blood viscosity (dependent on plasma 
viscosity and haematocrit) for cardiovascular events in 3386 men and women aged 
30 – 74 years followed up for 10 – 21 years [35]. High plasma viscosity was 
independently associated with CVD events and mortality. Although haematocrit 
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(mean ± SD: 0.4381 ± 0.0394) was significantly associated with CVD events (HR: 
1.14, 95% CI: 1.04 – 1.25, p=0.004) and mortality (HR: 1.22, 95% CI: 1.11 – 1.33, 
p<0.001) when adjusted only for age and gender, significance was lost when 
confounders such as lipids, blood pressure, diabetes, smoking status, family history 
of CVD and fibrinogen were included. 
A 34 year follow-up of 5209 men and women from the Framingham cohort indicated 
that the highest haematocrit quintile was associated with increased CVD and all-
cause mortality [36]. A dual effect was hinted at with a J or U shaped relationship 
between haematocrit and cardiovascular events. Further evidence for a non-linear 
association was added by Boffetta et al; in a study of 49,983 Iranian adults, a U-
shaped relationship between categories of haematocrit and mortality was found in 
both sexes, with both low and high values associated with increased overall mortality 
[37]. In males, compared to the reference group (haematocrit 0.40–0.44), all-cause 
mortality and mortality related to CVD were increased when the haematocrit was 
either below 0.39 or above 0.45 (adjusted Cox regression), whilst in females 
compared to the reference group (0.35–0.40), all-cause mortality was greater when 
haematocrit was below 0.35 or above 0.40 and mortality related to CVD greater 
when haematocrit was below 0.30 or above 0.40.
Locatelli et al studied the effects of erythropoietin in 5302 patients with end stage 
renal disease (mean baseline haematocrit ± SD: 0.301 ± 0.045) on the Lombardy 
Registry [38]. It was evident that all-cause mortality risk was inversely proportional to 
the increase in haematocrit (OR: 0.95, 95% CI: 0.92 – 0.97) following erythropoietin 
therapy.  It was concluded that a higher haematocrit achieved either spontaneously 
or following erythropoietin therapy improved outcomes in patients undergoing 
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dialysis.  The findings in patients with low baseline haematocrit may be compatible 
with speculation that the association between haematocrit and morbidity/mortality is 
non-linear, perhaps J or U shaped. However, cautious interpretation is needed as 
end stage renal disease patients are not at low mortality risk.  
Association between elevated haematocrit and T2DM
A further factor potentially linking haematocrit with mortality is its association with 
insulin resistance and impaired insulin secretion. This is important as adult onset TD 
is associated with T2DM with greater use of TTh in these patients and risk of further 
increased haematocrit levels. It is therefore, perhaps reasonable to consider T2DM 
patients as a subgroup when studying the clinical consequence of elevated 
haematocrit. Facchini et al. reported that increases in haematocrit and haemoglobin 
levels are associated with increased insulin resistance (by measuring steady-state 
plasma glucose levels after a 180-minute infusion of somatostatin, insulin and 
glucose), compensatory hyperinsulinaemia, elevated blood pressure, triglycerides 
and lower high density lipoprotein cholesterol values in 150 individuals [39]. When 
adjusted for all the above factors in a multiple regression analysis only insulin 
resistance and plasma insulin response to oral glucose remained associated with 
haematocrit and haemoglobin levels. In a prospective study of 7193 middle-aged 
men, Wannamethee et al. found an independent association between haematocrit 
and development of T2DM, independent of age, body mass index, smoking, physical 
activity, high density lipoprotein cholesterol, and systolic blood pressure [40]. T2DM 
was significantly higher in men with haematocrit levels ≥ 0.48 compared with levels 
<0.42 (RR: 4.5; 95% CI: 2.5-6.3, adjusted for age and body mass index). Even after 
further adjustment for predictors of T2DM with which hematocrit is correlated, there 
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remained a linear association with the risk of T2DM. The authors recommended that 
hematocrit, which is a major determinant of whole blood viscosity, should be added 
to the cluster of risk factors that link T2DM with CVD. As previously stated in the 
BLAST randomised controlled study HbA1c levels were not associated with baseline 
haematocrit levels.
Clearly, monitoring haematocrit levels in men on TTh is essential [4]. An haematocrit 
level of 0.54 has been accepted as the level at which down-titration / discontinuation 
of TTh is recommended. Although studies hint at an association between 
haematocrit, CVD and all-cause mortality there is no consensus view. 
It is reasonable to speculate that increased haematocrit levels result in altered blood 
flow characteristics that may lead to increased morbidity/mortality. Thus, it would be 
useful to characterise the blood flow changes that occur at different haematocrit 
levels in arteries varying in diameter. It is important that heterogeneity of disease 
pathogenesis is recognised since the adverse effects of TTh may only be seen in 
certain patient subgroups (Figure 2) [25]. Subgroups may be identified by broad 
phenotypes including age, diabetes and previous CVD as well as by those specific to 
adult onset TD and TTh; baseline testosterone and haematocrit, sexual health 
symptoms and other clinical consequences of hypotestosteronaemia. Subgroups 
may also be based on the extent of response to TTh  or use of concomitant 
treatments such as antihypertensives, statins and phosphodiesterase 5-inhibitors. In 
this way the appropriateness of using a haematocrit level of 0.54 as the sole cut-off 
for clinical intervention can be assessed.   
Effects of haematocrit on blood flow characteristics
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A change in haematocrit is likely to affect blood flow due to increased viscosity 
leading to altered endothelial function and perfusion. This may, in part, explain the 
negative outcomes reported in some studies of TTh. We now focus on some 
theoretical considerations of the effects of haematocrit on blood flow. Blood viscosity 
is a key factor determining blood flow. Blood is a multi-component fluid comprising 
cellular elements (platelets, leucocytes, erythrocytes) and plasma. Blood behaves as 
a non-Newtonian fluid exhibiting shear-thinning behaviour as well as being 
viscoelastic and thixotropic [41]. While plasma alone was considered a Newtonian 
fluid for decades, more recent studies have shown that blood plasma has a 
noticeable viscoelastic behaviour [42, 43]. Erythrocytes, which are deformable, 
constitute the majority of the suspended elements in blood and have a propensity to 
aggregate at low shear rates, forming rouleaux.
As with most particle suspensions the viscosity of whole blood depends primarily on 
haematocrit, erythrocyte aggregation and deformability [44]. Blood viscosity is 
reported to increase exponentially [45] or quadratically [46] with haematocrit with the 
effect of haematocrit being more pronounced at lower shear rates due to its effect on 
erythrocyte aggregation contributing further to the shear thinning behaviour [47]. Wall 
shear is known to be associated with activating endothelial function. Piety et al found 
that increasing the haematocrit of erythrocyte suspensions in plasma in vitro from 
20-60% resulted in a 3.5 fold increase in viscosity at a shear rate of 129 s-1 and a 
17.5 fold increase at 0.3 s-1 [48].  Empirical correlations and various concentration 
dependent models have been developed to describe this effect of haematocrit on 
blood viscosity [46,49, 50]. These will allow for improved of calculated wall shear 
stress in both micro and macrocirculation. 
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It is well established that the vascular bed affects haematocrit distribution with 
haematocrit levels being lower in the microvasculature. When blood flows from a 
large vessel to a small-diameter one (less than about 0.3 mm), the observed 
hematocrit level decrease is known as the Fåhræus effect [51]. The complex 
bifurcating microvascular architecture in conjunction with the particulate nature of 
blood gives rise to phenomena such as erythrocyte migration away from the wall and 
plasma skimming, resulting in higher flow rate branches receiving more cells and 
blood with a higher haematocrit [52]. This results in highly heterogeneous 
haematocrit distributions in the microcirculation that cause local variations in 
viscosity and flow resistance. This has been demonstrated in vivo [53] and in recent 
microfluidic studies of blood flow [54, 55].  
In addition to the Fåhræus effect the particulate nature of blood is also responsible 
for phenomena such as leucocyte and platelet margination [56] where these smaller 
cells are observed to migrate towards the vessel wall. Increased haematocrit could 
lead to more interactions between erythrocytes and leucocytes or platelets promoting 
margination.  Interestingly, Walton et al recently showed that elevated haematocrit in 
mice promoted arterial thrombosis perhaps due to rapid platelet accumulation within 
the thrombus [57]. 
Ageing and importantly T2DM in the context of TTh, can impair blood fluidity, altering 
tissue perfusion perhaps leading to functional deteriorations. It is well established 
that blood fluidity becomes impaired with age and erythrocyte life span [58, 59]. 
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Disorders such as sickle cell disease [60-62] and diabetes [63-67] have been 
associated with reduced erythrocyte deformability. 
Lower deformability of erythrocytes in T2DM has been associated with poor 
glycaemic control and microvascular complications such as diabetic retinopathy [68]. 
Erythrocytes in individuals with T2DM also undergo morphological changes with their 
shape deviating from the established biconcave disc to a more elongated shape [69]. 
These changes together with enhanced erythrocyte aggregation in T2DM can result 
in elevated blood viscosity which may be a factor in the pathogenesis of 
microvascular disease and non-flow limiting coronary artery disease [70, 71]. It is 
possible this risk is exacerbated by TTh associated increase in haematocrit. 
Changes in macrovascular flow characteristics that may be associated with 
increased haematocrit are also potentially important. Both end diastolic and peak 
systolic velocities have been associated with atherogenesis [72-76]. Our research 
group found that lower peak systolic velocity, based on ultrasound measurements in 
the carotid artery, was associated with coronary heart disease [72]. 
Optimal haematocrit
Salazar-Vazquez et al [77] suggested that the treatment of diabetes should target 
the maintenance of an optimal haematocrit in order to lower cardiovascular risk, 
prompting the question what is the ideal haematocrit? Clinical guidelines use a value 
<0.54 based on a population distribution and not physiological evaluation. Increased 
haematocrit should theoretically increase tissue oxygenation as oxygen content 
varies linearly with haematocrit. However, it also increases blood viscosity in an 
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exponential function reducing blood flow; hence an ideal haematocrit should exist 
that optimises tissue oxygenation and flow performance. A recent in vitro study 
concluded that the optimum haematocrit is different for large and small vessels, 
attributed to the difference in driving pressures and hence perfusion rates [48]. Many 
cardiovascular conditions result in lower blood flow rates either in systemic 
circulation or locally which might result in the optimal haematocrit being lower than 
the physiological one. This could be due to rheological changes brought about by 
impaired erythrocyte deformability or increased erythrocyte aggregation, endothelial 
dysfunction or decreased cardiac output [45]. An increase in haematocrit will 
increase whole blood viscosity which in turn will require a high blood pressure to 
maintain flow. Whilst the required increase in blood pressure can be quantified easily 
in vitro, the situation is more complex in vivo.  Factors such as altered vessel 
elasticity, endothelial function and release of vasodilators (e.g. nitric oxide) may 
influence the compensatory mechanisms. The above makes a case for individuals 
with T2DM to be considered as a subgroup since the efficiency of these factors may 
differ from that in health. In sickle cell anaemia, for example, the optimum 
haematocrit for transfusion has been set below 0.30 [78]. This implies that the 
optimum haematocrit in disease is subgroup specific and depends on the many 
factors impacting blood rheology. 
Therapeutic phlebotomy is the mainstay of controlling haematocrit in polycythaemia 
vera (PV). Some experts suggest haematocrit targets of < 0.45 in men and < 0.42 
percent in women [79-82]. A prospective trial randomly assigned 365 adults with PV 
to more intensive treatment (target haematocrit, < 0.45) versus less intensive 
treatment (target haematocrit: 0.45 – 0.50 percent); control of haematocrit achieved 
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by phlebotomy, hydroxyurea, or both. After a median follow-up of 31 months, 
compared with the more intensive therapy group, the less intensive therapy was 
associated with shorter time to death from CVD or major thrombotic events (HR: 3.9, 
95% CI: 1.5-10.5]; with events reported in 10% of the less intensive therapy group 
and 3 % in the more intensive treatment group [80].
Conclusion
Although TTh use has increased with most studies demonstrating benefit, doubts of 
its safety based on a few controversial reports of increased CVD remain. We have 
seen that increased haematocrit is the commonest adverse effect of TTh and 
guidelines regarding action thresholds are based on a population derived level of 
0.54. Longitudinal studies suggest that haematocrit influences CVD morbidity and 
mortality, although the association may not be linear. It is clear that further studies 
are required and we propose that in addition to clinical studies with hard and 
surrogate end-points, changes in blood flow characteristics should be evaluated 
across macro- and micro-circulatory vascular beds. 
Advanced computational tools are required to understand the particulate nature of 
blood in the microcirculation taking into account the impact of increased haematocrit 
and altered erythrocyte properties. Although this has been carried out in some 
pathologies (sickle cell anaemia [83], malaria [84]) only simple vascular geometries 
rather than networks were considered. Microfluidics has allowed microscale blood 
flow characteristics to be probed allowing cell and flow distribution to be resolved 
and phenomena such as erythrocyte aggregation and deformability on those to be 
Page 21 of 37
Sexual Medicine Reviews
Sexual Medicine Reviews
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
studied in detail [52, 53]. Thus, concurrent studies of clinical outcomes and 
evaluation of flow changes following haematocrit change during TTh in different 
patient groups will allow management guidance based on evidence that allows for 
patient heterogeneity.
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Figure 1: Change in haematocrit following 30 weeks of treatment in the 
placebo and TTh groups (BLAST study of men with T2DM). 
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Figure 2: A diagrammatic scheme of the importance of heterogeneity in complex diseases. 
This figure was previously published in: Ramachandran S, König CS, Hackett G, Livingston M, Strange RC. Managing clinical 
heterogeneity: An argument for benefit based action limits. Journal of Medical Diagnostics and Therapy 2018; 1: 034701 
(permission to use the figure was obtained from the journal)
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